Real-world experience with 240 mg of galcanezumab for the preventive treatment of cluster headache

BACKGROUND: Galcanezumab of 300 mg monthly is the FDA approved preventive medication for cluster headache (CH) during the cluster period. Compared to the 120 mg galcanezumab syringe for the treatment of migraines, the 100 mg syringe for CH has globally not been as widely available. The aim of our st...

Descripción completa

Detalles Bibliográficos
Autores principales: Mo, Heejung, Kim, Byung-Kun, Moon, Heui-Soo, Cho, Soo-Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9547445/
https://www.ncbi.nlm.nih.gov/pubmed/36209047
http://dx.doi.org/10.1186/s10194-022-01505-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9547445/
https://www.ncbi.nlm.nih.gov/pubmed/36209047
http://dx.doi.org/10.1186/s10194-022-01505-w

Ejemplares similares